Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Webcasts|March 9, 2021

Analytical Tools for PAT Implementation for the characterization of Biosimilars.

***Live: Europe Broadcast: Tuesday, March 9, 2021 at 9am EST | 2pm GMT | 3pm CET US Broadcast: Tuesday, March 9, 2021 2pm EST | 1pm CST | 11am PST*** This event will aim to present an overview of how analytical technologies can be adapted for implementation of Process Analytical Technology (PAT) in bioprocessing and how this can result in effective process control, thereby delivering consistent process performance and product quality.

Register Free: http://www.chromatographyonline.com/lcgc_w/adaption_tools

Event Overview:

This event will aim to present an overview of how analytical technologies can be adapted for implementation of Process Analytical Technology (PAT) in bioprocessing and how this can result in effective process control, thereby delivering consistent process performance and product quality.

Key Learning Objectives:

  • Introduction to PAT
  • Role of analytical technologies in PAT implementation
  • Case studies illustration successful PAT implementation

Speaker:

Anurag S. Rathore, Professor, Department of Chemical Engineering, Indian Institute of Technology

Time and Date:

Europe Broadcast: Tuesday, March 9, 2021 at 9am EST | 2pm GMT | 3pm CET

US Broadcast: Tuesday, March 9, 2021 2pm EST | 1pm CST | 11am PST

Sponsor: Agilent

Register Free: http://www.chromatographyonline.com/lcgc_w/adaption_tools


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.